Assessment of MGMT Promoter Methylation in Advanced Ewing Sarcoma Treated With Temozolomide and Irinotecan (MGMTLiberati)

Istituto Ortopedico Rizzoli

Status: Completed

Conditions: Ewing Sarcoma Family of Tumors

Treatments: Other: MGMT methylation evaluation

Study type: Observational

Funder types: Other

Identifiers

NCT03542097

TEMIRI-EW

Details and patient eligibility

About

This is a biological study in patients with advanced Ewing Sarcoma who received, according, clinical practice, temozolomide and irinotecan The O6-methylguanine-DNA methyltransferase (MGMT) methylation status, will be correlated with the disease clinical data and with the disease response

Full description

This is a biological study in patients with advanced Ewing Sarcoma who received, according, clinical practice, temozolomide and irinotecan.

The MGMT methylation status will be correlated with the disease clinical data and with the disease response also in term of metabolic activity (if data will be available) The MGMT methylation analysis will be performed extracting from fresh tumor sample, the DNA on the basis of the standard protocols.

Enrollment: 82 patients

Sex: All

Volunteers: No Healthy Volunteers

Inclusion criteria

1. Histological confirmed diagnosis of Ewing Sarcoma
2. Chemotherapic treatment with temozolomide and irinotecan
3. Written informed consent prior to any study related activities

Exclusion criteria

1. Lack of written informed consent for the study
2. Any situation that could interfere with the complete data collection of the clinical data related to the temozolomide and irinotecan treatment

Trial design

82 participants in 1 patient group

Temozolomide and Irinotecan treatment

Description:

The group include all the patients with histological confirmed diagnosis of Ewing's Sarcoma who received chemotherapic treatment with temozolomide and irinotecan. In this group the MGMT methylation evaluation will be done

Treatment:

Other: MGMT methylation evaluation